Literature DB >> 31305261

Is successful HIV therapy a Pyrrhic victory for the brain?

David B Clifford.   

Abstract

Neurologic involvement of HIV remains an important concern for patients, physicians, and investigators. Catastrophic decline is rarely seen in patients on combination antiretroviral therapy (cART); however, neurological decline remains a critical clinical challenge. In this issue of the JCI, Spudich and associates investigated the status of HIV in the cerebral spinal fluid (CSF) and revealed ongoing presence of HIV in the nervous system. Surprisingly, even in the face of optimal treatment, including suppressed HIV RNA, almost half of the patients investigated showed cell-associated HIV (CA-HIV) DNA in the CSF. Spudich et al. find that persistence of HIV in CSF cells is associated with lower performance on neurocognitive testing. These findings emphasize the need to consider a viral-associated mechanism as playing a significant and potentially ongoing role in HIV-associated neurocognitive disorder (HAND).

Entities:  

Year:  2019        PMID: 31305261      PMCID: PMC6668814          DOI: 10.1172/JCI127831

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

1.  Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance.

Authors:  Serena Spudich; Kevin R Robertson; Ronald J Bosch; Rajesh T Gandhi; Joshua C Cyktor; Hanna Mar; Bernard J Macatangay; Christina M Lalama; Charles Rinaldo; Ann C Collier; Catherine Godfrey; Joseph J Eron; Deborah McMahon; Jana L Jacobs; Dianna Koontz; Evelyn Hogg; Alyssa Vecchio; John W Mellors
Journal:  J Clin Invest       Date:  2019-07-15       Impact factor: 14.808

2.  The AIDS dementia complex: I. Clinical features.

Authors:  B A Navia; B D Jordan; R W Price
Journal:  Ann Neurol       Date:  1986-06       Impact factor: 10.422

3.  HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.

Authors:  R K Heaton; D B Clifford; D R Franklin; S P Woods; C Ake; F Vaida; R J Ellis; S L Letendre; T D Marcotte; J H Atkinson; M Rivera-Mindt; O R Vigil; M J Taylor; A C Collier; C M Marra; B B Gelman; J C McArthur; S Morgello; D M Simpson; J A McCutchan; I Abramson; A Gamst; C Fennema-Notestine; T L Jernigan; J Wong; I Grant
Journal:  Neurology       Date:  2010-12-07       Impact factor: 9.910

4.  Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons.

Authors:  E J Wright; B Grund; K Robertson; B J Brew; M Roediger; M P Bain; F Drummond; M J Vjecha; J Hoy; C Miller; A C Penalva de Oliveira; W Pumpradit; J C Shlay; W El-Sadr; R W Price
Journal:  Neurology       Date:  2010-08-11       Impact factor: 9.910

5.  Physical exercise is associated with less neurocognitive impairment among HIV-infected adults.

Authors:  Catherine A Dufour; Maria J Marquine; Pariya L Fazeli; Brook L Henry; Ronald J Ellis; Igor Grant; David J Moore
Journal:  J Neurovirol       Date:  2013-08-10       Impact factor: 2.643

6.  HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging.

Authors:  Beau M Ances; Florin Vaida; Melinda J Yeh; Christine L Liang; Richard B Buxton; Scott Letendre; J Allen McCutchan; Ronald J Ellis
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

7.  Longitudinal Trajectories of Brain Volume and Cortical Thickness in Treated and Untreated Primary Human Immunodeficiency Virus Infection.

Authors:  Ryan Sanford; Beau M Ances; Dieter J Meyerhoff; Richard W Price; Dietmar Fuchs; Henrik Zetterberg; Serena Spudich; D Louis Collins
Journal:  Clin Infect Dis       Date:  2018-11-13       Impact factor: 9.079

8.  Personalized Risk Index for Neurocognitive Decline Among People With Well-Controlled HIV Infection.

Authors:  Tracy Yuen; Marie-Josée Brouillette; Lesley K Fellows; Ronald J Ellis; Scott Letendre; Robert Heaton; Nancy Mayo
Journal:  J Acquir Immune Defic Syndr       Date:  2017-09-01       Impact factor: 3.771

9.  Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study.

Authors:  Robert K Heaton; Donald R Franklin; Reena Deutsch; Scott Letendre; Ronald J Ellis; Kaitlin Casaletto; Maria J Marquine; Steven P Woods; Florin Vaida; J Hampton Atkinson; Thomas D Marcotte; J Allen McCutchan; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Ned Sacktor; Susan Morgello; David M Simpson; Ian Abramson; Anthony C Gamst; Christine Fennema-Notestine; David M Smith; Igor Grant
Journal:  Clin Infect Dis       Date:  2014-10-31       Impact factor: 20.999

10.  Increased brain-predicted aging in treated HIV disease.

Authors:  James H Cole; Jonathan Underwood; Matthan W A Caan; Davide De Francesco; Rosan A van Zoest; Robert Leech; Ferdinand W N M Wit; Peter Portegies; Gert J Geurtsen; Ben A Schmand; Maarten F Schim van der Loeff; Claudio Franceschi; Caroline A Sabin; Charles B L M Majoie; Alan Winston; Peter Reiss; David J Sharp
Journal:  Neurology       Date:  2017-03-03       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.